Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Infratentorial Neoplasms 1Ependymoma 1Brain Neoplasms 1

Interventions

Radiosurgery 23Temozolomide 9Radiotherapy 8pembrolizumab 6Cyclophosphamide 6abemaciclib 5Nivolumab 5Radiation 4Mental Status and Dementia Tests 4Bevacizumab 4trastuzumab deruxtecan 3trametinib 3pertuzumab 3osimertinib 3entrectinib 3Surveys and Questionnaires 3Proton Therapy 3Magnetic Resonance Spectroscopy 3Lomustine 3Ipilimumab 3Immunoglobulin G 3Disulfides 3Cisplatin 3tucatinib 2encorafenib 2binimetinib 2Vincristine 2Trastuzumab 2Surgical Procedures, Operative 2Spermine Synthase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Brain Neoplasms × Craniospinal Irradiation × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡